Cerus (STU:CU2) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CU2 Cerus Corp STU:CU2
78 GF Score
Price €2.34
GF Value €1.97
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cerus Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cerus Valuation Rank Related Terms

STU:CU2
78GF Score
Cerus Corp STU:CU2
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cerus (STU:CU2) Overvalued in 2026?

Based on GuruFocus' analysis, Cerus stock appears to be overvalued. The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97. GuruFocus considers Cerus to be Modestly Overvalued.

Key valuation signals for STU:CU2:

  • Valuation Rank:
  • GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cerus Business Description

Other Exchanges CERS:USA
Address 1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score

Get the complete analysis for STU:CU2

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.34
Price
€1.97
GF Value